Amicus Therapeutics Inc (LTS:0HF9)
$ 9.978 -0.0808 (-0.8%) Market Cap: 2.98 Bil Enterprise Value: 3.18 Bil PE Ratio: 0 PB Ratio: 16.66 GF Score: 81/100

Q2 2024 Amicus Therapeutics Inc Earnings Call Transcript

Aug 08, 2024 / 12:30PM GMT
Release Date Price: $10.9 (+10.46%)
Operator

Good morning, ladies and gentlemen, and welcome to the Amicus Therapeutics second quarter 2024 financial results conference call and webcast. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, Mr. Andrew Faughnan, Vice President of Investor Relations. You may begin.

Andrew Faughnan
Amicus Therapeutics Inc - Vice President, Investor Relations

Thank you. Good morning and thank you for joining our conference call to discuss Amicus Therapeutics' second quarter 2024 financial results and corporate highlights. Leading today's call, we have Bradley Campbell, President and Chief Executive Officer; Sébastien Martel, Chief Business Officer; Dr. Jeff Castelli, Chief Development Officer; and Simon Harford, Chief Financial Officer. Joining for Q&A is Dr. Mitchell Goldman, Chief Medical Officer; and Ellen Rosenberg, Chief Legal Officer.

As referenced on slide 2, we may make forward-looking statements within this meaning of the Private Securities Litigation Reform

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot